Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
XFOR X4 Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: XFOR
Price (delayed)
$3.37
Market cap
$19.51M
P/E Ratio
1.57
Dividend/share
N/A
EPS
$2.14
Enterprise value
$57.29M
X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies for the treatment of diseases resulting from dysfunction of the CXCR4
Highlights
X4 Pharmaceuticals's net income has soared by 139% from the previous quarter and by 111% YoY
The EPS has soared by 138% since the previous quarter and by 110% year-on-year
The quick ratio has grown by 8% since the previous quarter but it has declined by 2% year-on-year
The debt has grown by 34% YoY
Key stats
What are the main financial stats of XFOR
Market
Valuations
Earnings
Shares outstanding
5.79M
Market cap
$19.51M
Enterprise value
$57.29M
Price to earnings (P/E)
1.57
Price to book (P/B)
0.85
Price to sales (P/S)
0.73
EV/EBIT
2.39
EV/EBITDA
2.13
EV/Sales
1.83
Revenue
$31.36M
Gross profit
$25.85M
Operating income
-$8.56M
Net income
$14.6M
EBIT
$24.02M
EBITDA
$26.84M
Free cash flow
-$119.94M
Per share
Balance sheet
Liquidity
EPS
$2.14
EPS diluted
$2.14
Free cash flow per share
-$17.53
Book value per share
$3.96
Revenue per share
$4.59
TBVPS
$15.04
Total assets
$130.01M
Total liabilities
$107.07M
Debt
$78.04M
Equity
$22.94M
Working capital
$69.81M
Debt to equity
3.4
Current ratio
3.7
Quick ratio
3.4
Net debt/EBITDA
1.41
Margins
Efficiency
Dividend
EBITDA margin
85.6%
Gross margin
82.4%
Net margin
46.5%
Operating margin
-27.3%
Return on assets
8.8%
Return on equity
29.3%
Return on invested capital
23.4%
Return on capital employed
23.1%
Return on sales
76.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
XFOR stock price
How has the X4 Pharmaceuticals stock price performed over time
Intraday
2.43%
1 week
-9.53%
1 month
-51.58%
1 year
-89.45%
YTD
-84.69%
QTD
-52.47%
Financial performance
How have X4 Pharmaceuticals's revenue and profit performed over time
Revenue
$31.36M
Gross profit
$25.85M
Operating income
-$8.56M
Net income
$14.6M
Gross margin
82.4%
Net margin
46.5%
X4 Pharmaceuticals's net income has soared by 139% from the previous quarter and by 111% YoY
The net margin has soared by 103% from the previous quarter
XFOR's operating margin has surged by 98% since the previous quarter
XFOR's operating income has soared by 93% year-on-year and by 76% since the previous quarter
Price vs fundamentals
How does XFOR's price correlate with its fundamentals
Growth
What is X4 Pharmaceuticals's growth rate over time
Valuation
What is X4 Pharmaceuticals stock price valuation
P/E
1.57
P/B
0.85
P/S
0.73
EV/EBIT
2.39
EV/EBITDA
2.13
EV/Sales
1.83
The EPS has soared by 138% since the previous quarter and by 110% year-on-year
The stock's price to book (P/B) is 94% less than its 5-year quarterly average of 13.1 and 67% less than its last 4 quarters average of 2.6
The equity has grown by 3.6% from the previous quarter
The P/S is 99% less than the last 4 quarters average of 96.4
Efficiency
How efficient is X4 Pharmaceuticals business performance
XFOR's return on invested capital has surged by 175% since the previous quarter and by 111% year-on-year
XFOR's return on assets has surged by 138% since the previous quarter and by 110% year-on-year
The company's return on equity has surged by 135% QoQ and by 111% YoY
The ROS has soared by 107% since the previous quarter
Dividends
What is XFOR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for XFOR.
Financial health
How did X4 Pharmaceuticals financials performed over time
XFOR's total assets is 21% greater than its total liabilities
XFOR's total assets is up by 16% year-on-year but it is down by 11% since the previous quarter
XFOR's total liabilities is down by 14% since the previous quarter and by 3.7% year-on-year
X4 Pharmaceuticals's debt to equity has plunged by 94% YoY and by 3.7% from the previous quarter
The debt has grown by 34% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.